Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550004 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
A Phase 2 study, sponsored by SciClone Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT00550004 is a Phase 2 study that was terminated before completion, run by SciClone Pharmaceuticals. The registered enrollment target is 153 participants.
The verdict
NCT00550004, a Phase 2 study, was terminated before completion, sponsored by SciClone Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South America. Approximately 153 subjects will be enrolled in a randomization (ratio 2:1).
Interventions
- DRUG RP101
- DRUG Gemcitabine (1000 mg/m2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550004
The ClinicalTrials.gov registry entry for NCT00550004 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SciClone Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RP101 is the first listed.
NCT00550004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550004 about?
NCT00550004 is a clinical study titled "Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine". This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South A...
What is the current status of trial NCT00550004?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2007-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00550004?
The interventions under investigation include: RP101 (DRUG), Gemcitabine (1000 mg/m2) (DRUG).
Who is sponsoring clinical trial NCT00550004?
This trial is sponsored by SciClone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.